牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析

doi:10.3969/j.issn.1672-5069.2019.06.019

Abstract

Abstract: Objective To systematically evaluate the efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease （NAFLD）. Methods We searched CNKI,VIP,WanFang Data,CBM,PubMed,The Cochrane Library,EMbase database and retrieved randomized controlled trials （RCT） on the observation of tauro ursodesoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with NAFLD since inception of database. Meta analysis was performed by using RevMan 5.3 software. Results A total of 682 NAFLD patients were included in 6 RCT studies,and 342 in the observation group were treated by tauro ursodesoxy cholic acid and polyene phosphatidyl choline,and 340 in the control group were treated by ursodeoxycholic acid and polyene phosphatidyl choline combination. The Results showed that the overall effective rate [RR=1.10,95%CI（1.03,1.18）,P=0.004],serum ALT reduction [MD=13.34,95%CI（12.20,14.48）,P<0.00001],AST reduction [MD=11.29,95%CI（5.85,16.72）,P<0.0001], GGT reduction [MD=22.54,95%CI（20.75,24.33）,P<0.00001],TG reduction[MD=0.48,95%CI（0.25,0.70）,P<0.0001],LDL-C reduction [MD=0.67,95%CI（0.51,0.83）,P<0.00001] and BMI reduction [MD=1.57,95%CI（1.29, 1.84）,P<0.00001] as well s HDL-C elevation [MD=0.23,95%CI（0.18,0.27）,P<0.00001] in the observation group in the treatment of patients with NAFLD were significantly superior to those in the control group; however,there was no significant difference between the two groups as respect to serum TC reduction [MD=0.30,95%CI（-0.03,0.64）,P=0.08] and the incidence of adverse reactions [RR=1.00,95%CI（0.41, 2.47）,P=1.00];the improvement of hepatic steatosis was also not significantly different between the two groups [RR=2.2,95%CI（0.97,4.98）,P=0.06]. Conclusion The efficacy of tauro ursodesoxy cholic acid combined with polyene phosphatidyl choline in the treatment of patients with NAFLD is good based on the domestic studies,which might be at a low level observations.

Key words: Non-alcoholic fatty liver, Tauroursodeoxycholic acid, Ursodeoxycholic acid, Therapy, Meta-analysis

Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis[J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.

References

[1] Rinella M.Nonalcoholic fatty liver disease:a systematic review. JAMA,2015,313(22):2263-2273.
[2] Diehl A,Day C.Cause,pathogenesis,and treatment of nonalcoholic steatohepatitis. N Engl J Med,2017,377(21): 2063-2072.
[3] Chalasani N,Younossi Z.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases. Hepatology,2018,67(1):328-357.
[4] Wong V,Chan W,Chitturi S,et al.Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1:definition,risk factors and assessment. J Gastroenterol Hepatol,2018,33(1):70-85.
[5] Fiorucci S,Biagtoli M,Distrutti E.Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacol Res,2018,134,289-298.
[6] Younossi Z,Koenig A,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence,incidence,and outcomes. Hepatology,2016,64(1): 73-84.
[7] Labrecque D,Abbas Z,Anania F,et al.World Gastroenterology Organisation global guidelines:nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol,2014,48(6):467-473.
[8] Ferramosca A,Di Giacomo M,Zara V.Antioxidant dietary approach in treatment of fatty liver:new insights and updates. World J Gastroenterol,2017,23(23):4146-4157.
[9] Townsend S,Newsome P.Review article:new treatments in non-alcoholic fatty liver disease. Aliment Pharmacol Ther,2017,46(5):494-507.
[10] Chitturi S,Wong V.The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2:management and special groups. J Gastroenterol Hepatol 2018,33(1):86-98.
[11] 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志,2018,21(2):177-186.
[12] 曹荣,胡旭东,柏涛,等. 熊去氧胆酸与牛磺熊去氧胆酸联合多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效比较. 中国药房,2013,24(4):365-367.
[13] 李志彬,徐莎,李霞,等. 两种熊去氧胆酸辅助多烯磷脂酰胆碱对非酒精性脂肪性肝炎患者血脂、肝功能指标及影像学改善的影响. 中西医结合肝病杂志,2016,26(4):219-221.
[14] 王军,胡翠兰,王哲,等. 牛磺熊去氧胆酸联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝病患者疗效观察. 实用肝脏病杂志,2015,18(5):544-545.
[15] 夏建萍,应豪. 两种熊去氧胆酸辅助多烯磷脂酰胆碱治疗NAFLD临床比较研究. 现代实用医学,2016,28(6):741-743.
[16] 许红华. 牛磺熊去氧胆酸治疗非酒精性脂肪肝效果探讨. 中国疗养医学,2017,26(9):900-902.
[17] 周健,刘黎,黄丽雯,等. 牛磺熊去氧胆酸治疗非酒精性脂肪肝疗效观察. 实用肝脏病杂志,2014,17(1):80-81.
[18] Lebeaupin C,Vallee D,Hazari Y,et al.Endoplasmic reticulum stress signaling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol,2018,69(4):927-947.
[19] Neuschwander-Tetri B.Non-alcoholic fatty liver disease. BMC Med,2017,15(1):45.
[20] 王宇明,于乐成. 肝脏炎症及其防治专家共识. 中国实用内科杂志,2014,34(2):152-162.
[21] Okiyama W,Tanaka N,Nakajma T,et al.Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress. J Hepatol,2009,50(6):1236-1246.
[22] 李笠,梁学亚. 水飞蓟宾葡甲胺联合多烯磷脂酰胆碱治疗酒精性脂肪肝患者初步临床研究. 实用肝脏病杂志,2017,20(4): 412-415.
[23] 陈潇迪,熊全,张霹云,等. 多烯磷脂酰胆碱对大鼠非酒精性脂肪性肝病的防治作用观察. 实用肝脏病杂志,2012,15(6):548-550.
[24] Jiang Q,Liu W,Li X,et al. Detection of related substances in polyene phosphatidyl choline extracted from soybean and in its commercial capsule by comprehensive supercritical fluid chromatography with mass spectrometry compared with HPLC with evaporative light scattering detection. J Sep Sci,2016,33509(2):-357.

Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[5]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[6]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[7]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[8]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[9]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[13]	Song Haiyan, Chen Xi, Zhang Junfei, et al. Application of vorionazole in the treatment of patients with liver failure complicated by pulmonary fungal infection [J]. Journal of Practical Hepatology, 2019, 22(5): 676-679.
[14]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[15]	Bian Xinqu, Chen Jie, Liu Yanmin, et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy [J]. Journal of Practical Hepatology, 2019, 22(5): 716-719.